ABBV · Abbvie Inc
United States · RS rating 95 · As of 2026-10-14
| Price | 283.48 USD |
|---|---|
| 1-day change | +3.3% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 92 / 87 / 79 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 51 / 59 / 55 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | +920.0% |
| Sales growth Q/Q | +5.3% |
| Distance from 52-week high | +0.0% |
| Market cap (USD) | $355.4B |